Justyna Wolska, Alicja Wolska, Edward Kowalczyk, Anna Wiktorowska-Owczarek

The role of proton pump inhibitors in renal disease - the risk of using OTC drugs
2019-06-03

Proton pump inhibitors (PPIs) are commonly prescribed drugs, pivotal in the therapy of various gastrointestinal tract conditions. PPIs irreversibly block the gastric hydrogen/potassium adenosinetriphosphatase enzyme system and thus inhibit gastric acid secretion. They are considered effective, safe and well-tolerated medications. However, long-term PPIs therapy might elevate the risk of serious adverse events, including adverse kidney outcomes. There is a strong relationship between PPI use and the risk of acute interstitial nephritis (AIN), acute kidney injury (AKI) and chronic kidney disease (CKD). This article, based on the latest reports, demonstrates the association between PPI therapy and kidney disease development, the appropriateness of the wide availability of OTC PPIs medications and the crucial role of pharmaceutical care in patient’s education.

Keywords: proton pump inhibitors, PPI, chronic kidney disease, acute kidney disease, interstitial nephritis.

© Farm Pol, 2019, 75 (5): 264–270